BriaCell (BCTX) T has received FDA clearance to initiate clinical evaluation of Bria-BRES+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for metastatic breast cancer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell presents anti-cancer activity of Bria-OTS
- BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR
- BriaCell Therapeutics Reports Rising Losses and Funding Pressure
- BriaCell to Spotlight Phase 3 Bria-IMT Data and Next-Gen Bria-OTS+ Platform at 2026 AACR
- BriaCell to present four posters at the 2026 AACR